Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Niraparib tosylate (MK-4827(tosylate)) 是一种高效的,具有生物口服利用度的PARP1和PARP2抑制剂,IC50分别为 3.8 和 2.1 nM。它抑制 DNA 损伤修复,诱导凋亡并具有抗肿瘤活性。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
2 mg | ¥ 398 | 现货 | ||
5 mg | ¥ 497 | 现货 | ||
10 mg | ¥ 872 | 现货 | ||
25 mg | ¥ 1,770 | 现货 | ||
50 mg | ¥ 3,390 | 现货 | ||
100 mg | ¥ 4,890 | 现货 | ||
500 mg | ¥ 9,870 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 557 | 现货 |
产品描述 | Niraparib tosylate (MK-4827 (tosylate))(with IC50 of 3.8 nM/2.1 nM) is a selective PARP1/PARP2 inhibitor. |
靶点活性 | PARP2:2.1 nM, PARP1:3.8 nM |
体外活性 | Micromolar concentrations of niraparib radiosensitizes tumor cell lines derived from lung, breast, and prostate cancers independently of their p53 status but not cell lines derived from normal tissues. Niraparib also sensitizes tumor cells to Water2 and converts Water2-induced single strand breaks (SSBs) into DSBs during DNA replication[5]. |
体内活性 | MK-4827 strongly enhances the effect of radiation on a variety of human tumor xenografts, both p53 wild type and p53 mutant. MK-4827 reduces PAR levels in tumors by 1 h after administration which persisted for up to 24 h[1]. In vivo treatment with MK-4827 and radiation prolonged survival (p<0.01) compared to single modalities. In vivo superiority of MK-4827 plus radiation is further documented by significant elevations of cleaved caspase-3 and γ-H2AX in tumors from the combination group compared to single modality cohorts[4]. |
激酶实验 | Enzyme assay is conducted in buffer containing 25 mM Tris, pH 8.0, 1 mM DTT, 1 mM spermine, 50 mM KCl, 0.01% Nonidet P-40, and 1 mM MgCl2. PARP reaction contains 0.1 μCi [3H]NAD+ (200 000 DPM), 1.5 μM NAD+, 150 nM biotinylated NAD+, 1 μg/mL activated calf thymus, and 1?5 nM PARP-1. Autoreactions utilizing SPA bead-based detection are carried out in 50 μL volumes in white 96-well plates. Compounds (e.g., MK-4827) are prepared in 11-point serial dilution in 96-well plate, 5 μL/well in 5% DMSO/Water (10× concentrated). Reactions are initiated by adding first 35 μL of PARP-1 enzyme in buffer and incubating for 5 min at room temperature and then 10 μL of NAD+ and DNA substrate mixture. After 3 h at room temperature, these reactions are terminated by the addition of 50 μL of streptavidin-SPA beads (2.5 mg/mL in 200 mM EDTA, pH 8). After 5 min, they are counted using a TopCount microplate scintillation counter. IC50 data is determined from inhibition curves at various substrate concentrations[1]. |
细胞实验 | V-C8 (BRCA2-negative) Chinese hamster cells are treated with the PARP inhibitor MK-4827 for 24 h, washed and incubated in drug-free medium for 5-7 days until colonies formed. (Only for Reference) |
别名 | 尼拉帕利, MK-4827 (tosylate), MK 4827 tosylate, Niraparib (MK-4827) tosylate, 尼拉帕尼对苯甲磺酸盐 |
分子量 | 492.59 |
分子式 | C19H20N4O·C7H8O3S |
CAS No. | 1038915-73-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 91 mg/mL (184.7 mM)
H2O: < 1 mg/mL (insoluble or slightly soluble)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.0301 mL | 10.1504 mL | 20.3009 mL | 50.7521 mL |
5 mM | 0.406 mL | 2.0301 mL | 4.0602 mL | 10.1504 mL | |
10 mM | 0.203 mL | 1.015 mL | 2.0301 mL | 5.0752 mL | |
20 mM | 0.1015 mL | 0.5075 mL | 1.015 mL | 2.5376 mL | |
50 mM | 0.0406 mL | 0.203 mL | 0.406 mL | 1.015 mL | |
100 mM | 0.0203 mL | 0.1015 mL | 0.203 mL | 0.5075 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Niraparib tosylate 1038915-73-9 Apoptosis Chromatin/Epigenetic DNA Damage/DNA Repair PARP 尼拉帕利 MK-4827 (tosylate) MK 4827 tosylate inhibit MK-4827 Tosylate MK4827 Niraparib Tosylate bioavailable cancer damage poly ADP ribose polymerase breast MK 4827 Tosylate Inhibitor MK-4827 anti-tumor orally ovarian Niraparib (MK-4827) tosylate MK4827 Tosylate 尼拉帕尼对苯甲磺酸盐 MK 4827 lung Niraparib DNA Niraparib (MK-4827) Tosylate inhibitor